ReviewFrontiers in pharmacology2025
Role and mechanism of botanical drugs and their metabolites in osteoporosis: new strategies for clinical application.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cuscuta chinensis Lam. extract alleviates ovariectomy-induced osteoporosis by inhibiting VCP-mediated METTL3 protein degradation.Journal of molecular histology · 2026Article
- Valorization of ligustrum species: biosynthesis, metabolic engineering, and pharmacology of bioactive compounds.Bioresources and bioprocessing · 2026Review
- Targeting ferroptosis in osteoporosis: mechanisms and natural products therapies.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis, the most prevalent bone disease worldwide, is characterized by reduced bone mineral density and microarchitectural deterioration. Current pharmacological agents for osteoporosis management include bisphosphonates, calcitonin, estrogen, denosumab, and romosozumab. However, emerging evidence suggests these therapies may increase risks of breast cancer, ovarian cancer, osteonecrosis, and cardiovascular diseases. Consequently, safer therapeutic alternatives are required. Traditional botanical drugs, recognized for their favorable safety profiles compared to synthetic drugs, demonstrate increasing potential in osteoporosis treatment. This review examines classical pathogenic mechanisms of osteoporosis-including estrogen deficiency, oxidative stress, and dysregulated bone metabolism-and summarizes traditional botanical drugs:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.